Human Hepatocellular response in Cholestatic Liver Diseases

References

• Hasegawa S, Yoneda M, Kurita Y, Nogami A, Honda Y, Hosono K, Nakajima A. Cholestatic liver disease: Current treatment strategies and new therapeutic agents. Drugs. 2021;81(10):1181–11. doi:10.1007/s40265-021-01545-7. Epub 20210617. PubMed PMID: 34142342; PMCID: PMC8282588.
   PubMed Web of Science ®Google Scholar
• Park JW, Kim JH, Kim SE, Jung JH, Jang MK, Park SH, Lee MS, Kim HS, Suk KT, Kim DJ. Primary biliary cholangitis and primary sclerosing cholangitis: Current knowledge of pathogenesis and therapeutics. Biomedicines. 2022;10(6). doi:10.3390/biomedicines10061288. Epub 20220531. PubMed PMID: 35740310; PMCID: PMC9220082.
   Web of Science ®Google Scholar
• Kwong AJ, Ebel NH, Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, Foutz J, Gauntt K, Cafarella M, et al. OPTN/SRTR 2020 annual data report: Liver. Am J Transplant. 2022;22:204–309. doi:10.1111/ajt.16978. PubMed PMID: WOS:000766695700005.
   PubMed Web of Science ®Google Scholar
• Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol. 2020;17(2):93–110. doi:10.1038/s41575-019-0226-7. Epub 20191209. PubMed PMID: 31819247.
   PubMed Web of Science ®Google Scholar
• de Vries AB, Janse M, Blokzijl H, Weersma RK. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol. 2015;21(6):1956–71. doi:10.3748/wjg.v21.i6.1956. PubMed PMID: 25684965; PMCID: PMC4323476.
   PubMed Web of Science ®Google Scholar
• Pollheimer MJ, Halilbasic E, Fickert P, Trauner M. Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2011;25(6):727–39. doi:10.1016/j.bpg.2011.10.009. PubMed PMID: 22117638; PMCID: PMC3236286.
   PubMed Web of Science ®Google Scholar
• Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56(5):1181–88. doi:10.1016/j.jhep.2011.10.025. Epub 20120113. PubMed PMID: 22245904.
   PubMed Web of Science ®Google Scholar
• Cazzagon N, Sarcognato S, Floreani A, Corra G, De Martin S, Guzzardo V, Russo FP, Guido M. Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis. JHEP Rep. 2021;3(3):100286. doi:10.1016/j.jhepr.2021.100286. Epub 20210330. PubMed PMID: 34041468; PMCID: PMC8141934.
   PubMedGoogle Scholar
• Tabibian JH, Trussoni CE, O’Hara SP, Splinter PL, Heimbach JK, LaRusso NF. Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis. Lab Invest. 2014;94(10):1126–33. doi:10.1038/labinvest.2014.94. Epub 20140721. PubMed PMID: 25046437; PMCID: PMC4184949.
   PubMed Web of Science ®Google Scholar
• Trussoni CE, O’Hara SP, LaRusso NF. Correction to: Cellular senescence in the cholangiopathies: a driver of immunopathology and a novel therapeutic target. Semin Immunopathol. 2022;44(4):545–46. doi:10.1007/s00281-022-00930-y. PubMed PMID: 35357519.
   PubMed Web of Science ®Google Scholar
• Wagner M, Trauner M. Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis. Ann Hepatol. 2005;4(2):77–99. doi:10.1016/S1665-2681(19)32071-X. PubMed PMID: 16010241.
   PubMedGoogle Scholar
• Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev. 2003;83(2):633–71. doi:10.1152/physrev.00027.2002. PubMed PMID: 12663868.
   PubMed Web of Science ®Google Scholar
• Faccioli LAP, Kocas-Kilicarslan ZN, Diaz-Aragon R, Motomura T, Amirneni S, Malizio MR, Coard MC, Frau C, Haep N, Florentino RM, et al. Human hepatocytes isolated from explanted livers: A powerful tool to understand end-stage liver disease and drug screening. Organogenesis. 2021;17(3–4):117–25. doi:10.1080/15476278.2021.1992216. PubMed PMID: 35114888; PMCID: PMC9208801.
   PubMed Web of Science ®Google Scholar
• Torres-Gonzalez M, Gawlowski T, Kocalis H, Scott BT, Dillmann WH. Mitochondrial 8-oxoguanine glycosylase decreases mitochondrial fragmentation and improves mitochondrial function in H9C2 cells under oxidative stress conditions. Am J Physiol Cell Physiol. 2014;306(3):C221–9. doi:10.1152/ajpcell.00140.2013. Epub 20131204. PubMed PMID: 24304833; PMCID: PMC3920001.
   PubMed Web of Science ®Google Scholar
• Brassea-Perez E, Hernandez-Camacho CJ, Labrada-Martagon V, Vazquez-Medina JP, Gaxiola-Robles R, Zenteno-Savin T. Oxidative stress induced by phthalates in mammals: State of the art and potential biomarkers. Environ Res. 2022;206:112636. doi:10.1016/j.envres.2021.112636. Epub 20211229. PubMed PMID: 34973198.
   PubMed Web of Science ®Google Scholar
• Gijbels E, Pieters A, De Muynck K, Vinken M, Devisscher L. Rodent models of cholestatic liver disease: A practical guide for translational research. Liver Int. 2021;41(4):656–82. doi:10.1111/liv.14800. Epub 20210223. PubMed PMID: 33486884; PMCID: PMC8048655.
   PubMed Web of Science ®Google Scholar
• Petrescu AD, DeMorrow S. Farnesoid X receptor as target for therapies to treat cholestasis-induced liver injury. Cells. 2021;10(8). doi:10.3390/cells10081846. Epub 20210721. PubMed PMID: 34440614; PMCID: PMC8392259.
   PubMed Web of Science ®Google Scholar
• Ye X, Zhang T, Han H. Ppar alpha: A potential therapeutic target of cholestasis. Front Pharmacol. 2022;13:916866. doi:10.3389/fphar.2022.916866. Epub 20220718. PubMed PMID: 35924060; PMCID: PMC9342652.
   PubMedGoogle Scholar
• Milkiewicz M, Klak M, Kempinska-Podhorodecka A, Wiechowska-Kozlowska A, Urasinska E, Blatkiewicz M, Wunsch E, Elias E, Milkiewicz P. Impaired hepatic adaptation to chronic cholestasis induced by primary sclerosing cholangitis. Sci Rep. 2016;6:39573. doi:10.1038/srep39573. Epub 20161223. PubMed PMID: 28008998; PMCID: PMC5180097.
   PubMed Web of Science ®Google Scholar
• Woolbright BL, Jaeschke H. Inflammation and cell death during cholestasis: The evolving role of bile acids. Gene Expr. 2019;19(3):215–28. doi:10.3727/105221619X15614873062730. Epub 20190628. PubMed PMID: 31253204; PMCID: PMC6827039.
   PubMed Web of Science ®Google Scholar
• Cai SY, Boyer JL. Studies on the mechanisms of bile acid initiated hepatic inflammation in cholestatic liver injury. Inflamm Cell Signal. 2017;4(2):e1561. Epub 20170619. PubMed PMID: 28804737; PMCID: PMC5553904.
   PubMedGoogle Scholar
• Cai SY, Ouyang X, Chen Y, Soroka CJ, Wang J, Mennone A, Wang Y, Mehal WZ, Jain D, Boyer JL. Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response. JCI Insight. 2017;2(5):e90780. doi:10.1172/jci.insight.90780. Epub 20170309. PubMed PMID: 28289714; PMCID: PMC5333973.
   PubMed Web of Science ®Google Scholar
• Schimming JP, Ter Braak B, Niemeijer M, Wink S, van de Water B. System microscopy of stress response pathways in cholestasis research. Methods Mol Biol. 2019;1981:187–202. doi:10.1007/978-1-4939-9420-5_13. PubMed PMID: 31016656.
   PubMedGoogle Scholar
• Terry C, Hughes RD, Mitry RR, Lehec SC, Dhawan A. Cryopreservation-induced nonattachment of human hepatocytes: role of adhesion molecules. Cell Transplant. 2007;16(6):639–47. doi:10.3727/000000007783465000. PubMed PMID: 17912955.
   PubMed Web of Science ®Google Scholar
• Malpique R, Ehrhart F, Katsen-Globa A, Zimmermann H, Alves PM. Cryopreservation of adherent cells: strategies to improve cell viability and function after thawing. Tissue Eng Part C Methods. 2009;15(3):373–86. doi:10.1089/ten.tec.2008.0410. PubMed PMID: 19196129.
   PubMed Web of Science ®Google Scholar
• Byun S, Kim DH, Ryerson D, Kim YC, Sun H, Kong B, Yau P, Guo G, Xu HE, Kemper B, et al. Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis. Nat Commun. 2018;9(1):2590. doi:10.1038/s41467-018-04697-5. Epub 20180703. PubMed PMID: 29968724; PMCID: PMC6030054.
   PubMedGoogle Scholar
• Schneider KM, Candels LS, Hov JR, Myllys M, Hassan R, Schneider CV, Wahlstrom A, Mohs A, Zuhlke S, Liao L, et al. Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling. Nat Metab. 2021;3(9):1228–41. doi:10.1038/s42255-021-00452-1. Epub 20210922. PubMed PMID: 34552267.
   PubMedGoogle Scholar
• Haep N, Florentino RM, Squires JE, Bell A, Soto-Gutierrez A. The inside-out of end-stage liver disease: hepatocytes are the keystone. Semin Liver Dis. 2021;41(2):213–24. doi:10.1055/s-0041-1725023. Epub 20210515. PubMed PMID: 33992030; PMCID: PMC8996333.
   PubMedGoogle Scholar
• Tovey MG, Gugenheim J, Guymarho J, Blanchard B, Vanden Broecke C, Gresser I, Bismuth H, Reynes M. Genes for interleukin-1, interleukin-6, and tumor necrosis factor are expressed at markedly reduced levels in the livers of patients with severe liver disease. Autoimmunity. 1991;10(4):297–310. doi:10.3109/08916939109001904. PubMed PMID: 1772964.
   PubMed Web of Science ®Google Scholar
• Jonker JW, Liddle C, Downes M. FXR and PXR: potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol. 2012;130(3–5):147–58. doi:10.1016/j.jsbmb.2011.06.012. Epub 20110720. PubMed PMID: 21801835; PMCID: PMC4750880.
   PubMed Web of Science ®Google Scholar
• Wei S, Ma X, Zhao Y. Mechanism of hydrophobic bile acid-induced hepatocyte injury and drug discovery. Front Pharmacol. 2020;11:1084. doi:10.3389/fphar.2020.01084. Epub 20200716. PubMed PMID: 32765278; PMCID: PMC7378542.
   PubMed Web of Science ®Google Scholar